IN THE CLAIMS:

Claim 1 (Currently Amended) A method of treatment of Parkinson's disease ~~for treating, preventing the progression, ameliorating, controlling or reducing the risk of a movement disorder~~ in a patient in need thereof that comprises administering to the patient a therapeutically effective amount of an mGluR4 receptor positive allosteric modulator or a pharmaceutically acceptable salt thereof.

Claim 2 (Previously Canceled)

Claim 3 (Withdrawn) The method of Claim 1 wherein the movement disorder is selected from the group consisting of Parkinson's disease, dyskinesia, tardive dyskinesia, drug-induced parkinsonism, postencephalitic parkinsonism, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, parkinsonian-ALS dementia complex, basal ganglia calcification, akinesia, akinetic-rigid syndrome, bradykinesia, dystonia, medication-induced parkinsonia, Gilles de la Tourette syndrome, Huntington's disease, tremor, chorea, myoclonus, tick disorder, and dystonia.

Claims 4-5 (Previously Canceled)

Claim 6 (Withdrawn) The method of Claim 1 wherein the mGluR4 receptor positive allosteric modulator or a pharmaceutically acceptable salt thereof, is administered in combination with an agent selected from the group consisting of: levodopa, levodopa with a selective extracerebral decarboxylase inhibitor, carbidopa, entacapone, an anticholinergic, a COMT inhibitor, an A2a adenosine receptor antagonist, a cholinergic agonist, a dopamine agonist, a butyrophenone neuroleptic agent, a

diphenylbutylpiperidine neuroleptic agent, a heterocyclic dibenzazepine neuroleptic agent, a indolone neuroleptic agent, a phenothiazine neuroleptic agent, a thioxanthene neuroleptic agent, an NMDA receptor antagonist, a metabotropic glutamate receptor potentiator and a metabotropic glutamate receptor agonist.

Claim 7 (Withdrawn) The method of Claim 1 wherein the mGluR4 receptor positive allosteric modulator or a pharmaceutically acceptable salt thereof, is administered in combination with a compound selected from the group consisting of: acetophenazine, alentemol, benzhexol, bromocriptine, biperiden, chlorpromazine, chlorprothixene, clozapine, diazepam, fenoldopam, fluphenazine, haloperidol, levodopa, levodopa with benserazide, levodopa with carbidopa, lisuride, loxapine, mesoridazine, molindolone, naxagolide, olanzapine, pergolide, perphenazine, pimozide, pramipexole, risperidone, sulpiride, tetrabenazine, trihexyphenidyl, thioridazine, thiothixene and trifluoperazine.

Claims 8-9 (Previously Canceled)

Claim 10 (Previously presented) The method of Claim 1 wherein the mGluR4 receptor positive allosteric modulator is N-phenyl-7-(hydroxylimino)cyclo-propa[b]chromen-la-carboxamide.

Claim 11 (Withdrawn) A pharmaceutical composition comprising an mGluR4 receptor positive allosteric modulator or a pharmaceutically acceptable salt thereof and an antiparkinsonian agent, and a pharmaceutically acceptable carrier or excipient.

Claim 12 (Withdrawn) A pharmaceutical composition comprising an mGluR4 receptor positive allosteric modulator or a pharmaceutically acceptable salt thereof and a neuroleptic agent, and a pharmaceutically acceptable carrier or excipient.

Claim 13 (Previously Canceled)

Claim 14 (Withdrawn) The method of Claim 1 wherein the movement disorder is Parkinson's Disease.

Claim 15 (Withdrawn) The method of Claim 1 wherein the movement disorder is an akinetic rigid disorder.

Claim 16 (Withdrawn) The method of Claim 1 wherein the movement disorder is dyskinesia.

Claim 17 (Withdrawn) The method of Claim 15, wherein the patient in need thereof is non-responsive to antiparkinsonian agents or is a patient for whom antiparkinsonian agents are contraindicated.

Claim 18 (Withdrawn) The method of Claim 16, wherein the patient in need thereof is non-responsive to neuroleptic agents or is a patient for whom neuroleptic agents are contraindicated.

Claim 19 (New) The method of Claim 1, wherein the mGluR4 receptor positive allosteric modulator possesses a selectivity for the mGluR4 receptor relative to each of the other mGluR receptors by at least three to 300 fold or greater as measured by the ratio of EC_{50} .

Claim 20 (New) The method of Claim 1, wherein the mGluR4 receptor positive allosteric modulator possesses an EC_{50} for binding to the mGluR4 receptor of 1 uM to 1 nM or less as evaluated by the FLIPR assay.

Claim 21 (New) The method of Claim 1, wherein the mGluR4 receptor positive allosteric modulator is a non-peptidyl mGluR4 receptor positive allosteric modulator.

Claim 22 (New) The method of Claim 1, wherein the mGluR4 receptor positive allosteric modulator is a peptidyl mGluR4 receptor positive allosteric modulator.

Claim 23 (New) The method of Claim 1, wherein the mGluR4 receptor positive allosteric modulator is a compound that exhibits sufficient concentration in the central nervous system to have a therapeutic efficacy upon oral administration.